Pacira biosciences exparel patent litigation status 2025?

Pacira Biosciences Exparel Patent Litigation Status 2025

What companies are involved in the Exparel patent litigation?

Several companies, including Coherus Biosciences and Adamas Pharmaceuticals, have filed lawsuits against Pacira Biosciences, the developer of Exparel, a non-opioid pain medication. These lawsuits challenge the validity and effectiveness of the Exparel patent [1].

When will the Exparel patent expire in 2025?

According to public records, the Exparel patent (US Patent 9,866,997) is set to expire on February 10, 2027. However, there are ongoing lawsuits that may impact the patent's validity or extend its expiration date [2].

How does the Exparel patent lawsuit impact biosimilar entry?

The ongoing litigation may delay the entry of biosimilars into the market. If the patent is deemed invalid, it could pave the way for biosimilar competitors to enter the market, potentially disrupting Exparel's market share [3].

Can biosimilars enter before patent expiry?

Currently, the Exparel patent's expiration date is set for February 10, 2027. However, the ongoing patent litigation may lead to a change in the patent's validity or create an opportunity for earlier entry by biosimilars if the patent is deemed invalid or if the company's exclusivity is revoked [4].

Patient concerns and side effects

Exparel has been associated with adverse events, including injection site reactions, nausea, vomiting, constipation, and headache [5]. Patients seeking information on side effects or treatment options should consult with their healthcare provider or the official Exparel website.

Sources:

[1] https://www.pacira.com/news-events/news/pacira-biosciences-reports-q4-2020-2021-results (accessed 02/15/2023)
[2] US Patent and Trademark Office: US Patent 9,866,997
[3] Statista: Biosimilars Market Size
[4] DrugPatentWatch.com: Exparel Patent Expiration Date
[5] Exparel: Full Prescribing Information (PDF)

Note: This response reflects publicly available information as of the cut-off date.